# Efficacies of Entecavir Add on HBeAg Negative Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment

> **NCT02365402** · PHASE4 · UNKNOWN · sponsor: **Beijing Ditan Hospital** · enrollment: 180 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Entecavir

## Key facts

- **NCT ID:** NCT02365402
- **Lead sponsor:** Beijing Ditan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-01
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2016-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02365402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02365402, "Efficacies of Entecavir Add on HBeAg Negative Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02365402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*